Table 3 Baseline characteristics by sex in persistent AF
Variables | Total (n = 381) | Male (n = 267) | Female (n = 114) | P value |
|---|---|---|---|---|
Age, years, Mean (SD) | 60.6 ± 10.3 | 59.1 ± 10.4 | 64.2 ± 9.1 | < 0.001 |
BMI, kg/m2, Mean (SD) | 25.6 ± 3.5 | 25.7 ± 3.4 | 25.5 ± 3.8 | 0.491 |
AF duration, m (IQR) | 12 (3–48) | 12 (3–48) | 12 (3–36) | 0.579 |
Concomitant medical history, n (%) | Â | Â | Â | Â |
 Hypertension | 170 (44.6) | 111 (41.6) | 59 (51.8) | 0.072 |
 Diabetes mellitus | 46 (12.1) | 35 (13.1) | 11 (9.6) | 0.394 |
 History of stroke/TIA | 32 (8.4) | 24 (9) | 8 (7) | 0.687 |
 Chronic heart failure | 47 (12.3) | 34 (12.7) | 13 (11.4) | 0.865 |
 Coronary artery disease | 160 (18.7) | 97 (18.1) | 63 (19.7) | 0.587 |
AAD post-ablation, n (%) | 337 (88.5) | 237 (88.8) | 100 (87.7) | 0.770 |
amiodarone, n (%) | 326 (85.6) | 228 (85.4) | 98 (86) | 0.884 |
propafenone, n (%) | 15 (3.9) | 12 (4.5) | 3 (2.6) | 0.570 |
LAD, mm, Mean (SD) | 40.1 ± 6.0 | 40 ± 5.8 | 39.5 ± 6.4 | 0.178 |
LVEDD, mm, Mean (SD) | 49 ± 5.4 | 50 ± 5.3 | 46.9 ± 5.1 | < 0.001 |
LVEF, %, Mean (SD) | 54.1 ± 7.2 | 53.9 ± 7.6 | 54.6 ± 6.2 | 0.823 |
Ablation time, min (IQR) | 120 (92.5–169) | 120 (94–167) | 122 (87–180) | 0.969 |
LAV, ml (IQR) | 114 (96-139.1) | 115.5 (96.3-142.1) | 113.5 (95–134) | 0.225 |
LAVI, ml /m2 (IQR) | 62.8 (53.8–77.7) | 62 (53-75.3) | 65.8 (55.6–79.2) | 0.016 |
extraPV ablation, n (%) | 61 (16) | 37 (13.9) | 24 (21.1) | 0.093 |
Follow-up, m (IQR) | 50 (36–71) | 48 (36-69.5) | 52.5 (35–74) | 0.557 |
ATa recurrence, n (%) | 140 (36.7) | 84 (31.5) | 56 (49.1) | 0.001 |